Arvinas, Inc.

Arvinas, Inc.

Arvinas, Inc.

Overview
Date Founded

2013

Headquarters

395 Winchester Avenue, 5 Science Park, New Haven, CT, 06511, USA

Type of Company

Public

Employees (Worldwide)

83

Industries

Biotechnology

Company Description

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Executives & Employees

Chief Executive Officer, President & Director

Chief Financial Officer & Principal Accounting Officer

Chief Technology Officer

Chief Scientific Officer

Chief Medical Officer

Vice President-Information Technology

Vice President-Business Development & Counsel

Manager

Manager

Board of Directors

Venture Partner at Canaan Management, Inc.

Strategic Advisor at National Health Advisors

Executive Partner at Mpm Capital LLC

Managing Partner at 5AM Venture Management LLC

Head of Access Biotechnology at Access Industries, Inc. - New York

Co-Founder & Chief Executive Officer at Cerevance LLC

Partner at Nextech Invest AG

Member (Attorney) at Epstein Becker & Green PC

Chief Executive Officer, President & Director at Arvinas, Inc.

Paths to Arvinas, Inc.
Potential Connections via
Relationship Science
You
Arvinas, Inc.
Owners & Shareholders
Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Details Hidden

New Leaf Ventures Partners focuses exclusively in healthcare companies located in the US with strong management teams and revenues exceeding $100 million. They targets companies operating in the fields of biopharmaceutical, information convergence (HCIT), medical device and life science tools.The firm provides financing for early and later stage capital requirements and invests in both public & private companies.

Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Recent Transactions
Details Hidden

Arvinas, Inc. issued USD Common Stock

Details Hidden

Arvinas, Inc. raised money in a private placement transaction

Details Hidden

Arvinas, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Transaction Advisors
Underwriter

Advised onArvinas, Inc. issued USD Common Stock

Escrow Agent

Advised onArvinas, Inc. issued USD Common Stock

Auditor

Advised onArvinas, Inc. issued USD Common Stock

Legal Advisor

Advised onArvinas, Inc. issued USD Common Stock

Clients

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Key Stats and Financials As of 2018
Market Capitalization
$837M
Total Enterprise Value
$-64.6M
Earnings Per Share
$-25.45
Revenue
$14.3M
EBITDAMargin
-300.87%
Total Equity
$137M
Total Debt
$2.15M
EBITDA
$-43.1M
Net Profit
$-41.5M
Enterprise Value Sales
-4.51x
TEVNet Income
1.56x
Debt TEV
-0.03x
Investors
Details Hidden

New Leaf Ventures Partners focuses exclusively in healthcare companies located in the US with strong management teams and revenues exceeding $100 million. They targets companies operating in the fields of biopharmaceutical, information convergence (HCIT), medical device and life science tools.The firm provides financing for early and later stage capital requirements and invests in both public & private companies.

Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Deerfield Management Co. LP (Private Equity) invests in a broad range of industries. It provides financing for buyout transactions to private and public companies located in the U.S.

Suppliers
Yale University Internet Software & Services | New Haven, CT

Yale University is an American private Ivy League research university located in New Haven, Connecticut. Founded in 1701 in the Colony of Connecticut, the university is the third-oldest institution of higher education in the United States.

Competitors
GlaxoSmithKline Plc Pharmaceuticals - Brentford, Middlesex

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Arvinas, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Arvinas, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Arvinas, Inc..